Health Care & Life Sciences » Biotechnology | Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Regeneron Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard Health Care Fund
3,110,825
2.93%
66,500
2.52%
06/30/2018
Vanguard Total Stock Market Index Fund
1,997,122
1.88%
9,542
0.11%
07/31/2018
American Funds Growth Fund of America
1,722,000
1.62%
722,000
0.38%
06/30/2018
American Funds Fundamental Investors
1,502,279
1.42%
199,979
0.67%
06/30/2018
Vanguard 500 Index Fund
1,400,427
1.32%
1,740
0.13%
07/31/2018
American Funds New Perspective Fund
1,318,000
1.24%
112,303
0.65%
06/30/2018
Oakmark Fund
1,261,796
1.19%
517,996
2.5%
06/30/2018
American Funds Insurance Series - Growth Fund
1,194,000
1.12%
300,000
1.85%
06/30/2018
iShares Nasdaq Biotechnology ETF
1,161,449
1.09%
-15,183
4.82%
09/06/2018
PowerShares QQQ Trust
887,099
0.84%
-3,472
0.49%
09/05/2018

About Regeneron Pharmaceuticals

View Profile
Address
777 Old Saw Mill River Road
Tarrytown New York 10591
United States
Employees -
Website http://www.regeneron.com
Updated 07/08/2019
Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases. It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP. The company was founded by Alferd G.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.